It was suggested that the RUNX1/FLI1 complex negatively regulates ANKRD26 expression and that mutations in 5′-UTR of ANKRD26 disrupt RUNX1/FLI1 inhibition, which would lead to overexpression of ANKRD26 in megakaryocytes and defective proplatelet formation, and thus thrombocytopenia in patients (Balduini et al., 2018; Bluteau et al., 2014). This evidence concerns the gene ANKRD26 and Thrombocytopenia.